ATCC Announces DTRA Awards That Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense
New work on small molecule antiviral therapies using artificial intelligence and machine learning for drug design and organoids for testing
MANASSAS, Virginia–(BUSINESS WIRE)– ATCC, the world’s premier biological materials management and standards organization, announced that it has received three grants worth more than $5.5 million from the Defense Threat Reduction Agency (DTRA ) the United States. The work will identify and characterize novel therapeutic approaches against viruses of global health concern. Promising therapeutic candidates will be tested for their efficacy with in vitro and live model systems.
“ATCC is committed to supporting this global health initiative by providing the new scientific research and development solutions needed to address these high morbidity and mortality infectious diseases,” said Raymond H. Cypess, DVM, Ph. .D., President and CEO. of the ATCC. “Through our new partnership with DTRA, we now have the opportunity to focus on the development of new machine learning (ML) and artificial intelligence (AI) models for the identification of countermeasures that could lead to better vaccine and therapeutic solutions, necessary to save lives.”
Specifically, ATCC’s role will be to use multiple experimental platforms to define novel therapeutic targets, evaluate novel and/or FDA-approved candidates for antiviral and anti-inflammatory activities, and define relevant biomarkers. associated with infections. This information will be used to develop AI models of disease and therapeutic efficacy. ATCC will also use ML/AI strategies to integrate cellular response datasets and identify broad-spectrum therapeutic candidates to combat various pathogens. Promising candidates will be tested with new organoid (organ-on-a-chip) models in an iterative and sequential transition from in vitro for live platforms. This is considered a critical step in the one-drug-many-bugs approach to antiviral product development and will be an important contribution to improving our country’s pandemic preparedness resilience in the face of current and future challenges.
“ATCC is proud to provide its global health and biodefense expertise to support federal infectious disease research and development programs and the DoD with this new grant from DTRA,” said Joseph Leonelli, Ph.D. , senior vice president of ATCC Federal Solutions (AFS).
Dr. Aarthi Narayanan, Director of Translational Research and Technology Transfer at ATCC, will lead this research. She brings her deep expertise in virology and preclinical product development to the AFS team and oversees the translation of cutting-edge research into technologies and products that will continue to improve global health and biodefense.
About the ATCC
The ATCC is one of the world’s leading resource and standards organizations for biological materials and information and the leading developer and provider of authenticated cell lines and microorganisms. With a history of scientific advancements spanning nearly a century, ATCC offers an unparalleled combination of being the world’s largest and most diverse collection of biological research solutions and a mission-focused trusted partner that supports and encourages scientific collaboration. ATCC’s products, services, and people provide the scientific community with credible biologics, advanced model systems, and custom solutions that support complex research in a variety of innovative applications, resulting in incredible achievements in the fields of basic science, drug discovery, translational medicine and public health. ATCC is a non-profit organization with headquarters in Manassas, VA, and an R&D innovation center in Gaithersburg, MD. To learn more, visit atcc.org.